Ampyra for Optic Neuritis in MS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01337986
Recruitment Status : Completed
First Posted : April 19, 2011
Last Update Posted : February 19, 2014
Acorda Therapeutics
Information provided by (Responsible Party):
Robert Naismith, Washington University School of Medicine

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : December 2013
  Actual Study Completion Date : December 2013

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 May 4, 2016
June 17, 2016
2 February 14, 2018
March 15, 2018
Farnsworth D. The Farnsworth-Munsell 100-hue and dichotomous tests for color vision. J Opt Soc Am 1943;33:568-574.
Acorda Therapeutics. AMPRYA package insert (2010).